(VIANEWS) – SPS Commerce (SPSC), Yelp (YELP), WEX (WEX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SPS Commerce (SPSC)
16.3% sales growth and 11.06% return on equity
SPS Commerce, Inc. provides cloud-based supply chain management solutions worldwide. It offers solutions through the SPS Commerce, a cloud-based platform that enhances the way retailers, suppliers, grocers, distributors, and logistics firms manage and fulfill omnichannel orders, optimize sell-through performance, and automate new trading relationships. The company also provides Fulfillment solution, an electronic data interchange solution that scales as a business grows, where companies use a single system to manage orders and logistics from various sales channels, including wholesale, eCommerce, and marketplaces; and Analytics product that enables organizations to enhance visibility into how products are selling through a single connection across various sales channels, including wholesale, eCommerce, and marketplaces, as well as enhances access and usage of sales and inventory data through a combination of analytics applications, network of connections, and industry-leading expertise. In addition, it offers various complimentary products, such as assortment product, which simplifies the communication of robust, accurate item data by automatically translating item attributes, and hierarchies; and community product that allows organizations to accelerate digitization of their supply chain and improve collaboration with suppliers through change management and onboarding programs. The company was formerly known as St. Paul Software, Inc. and changed its name to SPS Commerce, Inc. in May 2001. SPS Commerce, Inc. was incorporated in 1987 and is headquartered in Minneapolis, Minnesota.
Earnings Per Share
As for profitability, SPS Commerce has a trailing twelve months EPS of $1.69.
PE Ratio
SPS Commerce has a trailing twelve months price to earnings ratio of 103.64. Meaning, the purchaser of the share is investing $103.64 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.06%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 9.5% and 10.4%, respectively.
Previous days news about SPS Commerce(SPSC)
- According to Zacks on Tuesday, 21 November, "While Huron Consulting sports a Zacks Rank #1 (Strong Buy), SPS Commerce and Parsons carry a Zacks Rank #2 (Buy) at present. ", "Shares of Huron Consulting, SPS Commerce and Parsons have gained 38.1%, 30.8% and 29%, respectively, in the past year."
2. Yelp (YELP)
10% sales growth and 12.76% return on equity
Yelp Inc. operates a platform that connects consumers with local businesses in the United States and internationally. The company's platform covers various local business categories, including restaurants, shopping, beauty and fitness, health, and other categories, as well as home, local, auto, professional, pets, events, real estate, and financial services. It provides free and paid advertising products to businesses, which include cost-per-click search advertising and multi-location Ad products, as well as enables businesses to deliver targeted search advertising to local audiences; and business listing page products. The company also offers other services comprising Yelp Guest Manager, a subscription-based suite of front-of-house management tools for restaurants, nightlife and certain other venues, which include online reservations, a waitlist management solution that allows consumers to check wait times and join waitlists remotely as well as through hostless kiosks, and seating and server rotation management tools; Yelp Knowledge program that offers business owners local analytics and insights through access to its historical data and other proprietary content; and Yelp Fusion, which offers free and paid access to content and data for consumer-facing enterprise use through publicly available APIs. In addition, it provides content licensing, as well as allows third-party data providers to update and manage business listing information on behalf of businesses. Further, the company offers its products directly through its sales force; indirectly through partners; and online through its website and business app, as well as non-advertising partner arrangements. It has partnership with Grubhub for providing consumers with a service to place food orders for pickup and delivery. The company was incorporated in 2004 and is headquartered in San Francisco, California.
Earnings Per Share
As for profitability, Yelp has a trailing twelve months EPS of $1.26.
PE Ratio
Yelp has a trailing twelve months price to earnings ratio of 36.38. Meaning, the purchaser of the share is investing $36.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.76%.
Volume
Today’s last reported volume for Yelp is 535688 which is 9.19% below its average volume of 589926.
Yearly Top and Bottom Value
Yelp’s stock is valued at $45.84 at 04:22 EST, below its 52-week high of $47.59 and way above its 52-week low of $25.30.
3. WEX (WEX)
9.1% sales growth and 16.25% return on equity
WEX Inc. operates a commerce platform in the United States and internationally. The Fleet Solutions segment offers fleet vehicle payment solutions, transaction processing, and information management services. It also provides account and account retention services; authorization and billing inquiries, and account maintenance services; account management; credit and collections services; merchant services; analytics solutions; and ancillary services and tools to fleets to manage expenses and capital requirements. This segment markets its products directly and indirectly to businesses and government agencies with fleets of commercial vehicles; and indirectly through co-branded and private label relationships. The Travel and Corporate Solutions segment provides payment solutions, including embedded payments; and accounts payable automation and spend management solutions. Its products include virtual cards that are used for transactions where no physical card is presented. This segment markets its products directly and indirectly to customers in travel, fintech, insurance, consumer bill pay, and media verticals, as well as businesses and financial institutions. The Health and Employee Benefit Solutions segment offers software-as-a-service (SaaS) platform for consumer directed healthcare benefits and full-service benefit enrollment solutions. Its SaaS platform includes embedded payment solutions and plan administration services for consumer-directed health benefits; COBRA accounts; and benefit enrollment and administration services. This segment also provides custodial and depository services for health savings accounts; and payroll-related benefits. This segment markets its products through third-party administrators, financial institutions, payroll providers, and health plans. The company was formerly known as Wright Express Corporation and changed its name to WEX Inc. in October 2012. WEX Inc. was founded in 1983 and is based in Portland, Maine.
Earnings Per Share
As for profitability, WEX has a trailing twelve months EPS of $6.17.
PE Ratio
WEX has a trailing twelve months price to earnings ratio of 28.26. Meaning, the purchaser of the share is investing $28.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.25%.
Moving Average
WEX’s worth is below its 50-day moving average of $185.06 and under its 200-day moving average of $184.19.
4. Regeneron Pharmaceuticals (REGN)
7.4% sales growth and 17.22% return on equity
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Earnings Per Share
As for profitability, Regeneron Pharmaceuticals has a trailing twelve months EPS of $35.07.
PE Ratio
Regeneron Pharmaceuticals has a trailing twelve months price to earnings ratio of 22.87. Meaning, the purchaser of the share is investing $22.87 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.22%.
Sales Growth
Regeneron Pharmaceuticals’s sales growth is negative 4.6% for the present quarter and 7.4% for the next.
Yearly Top and Bottom Value
Regeneron Pharmaceuticals’s stock is valued at $802.11 at 04:22 EST, below its 52-week high of $853.97 and way above its 52-week low of $668.00.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.5%, now sitting on 13.1B for the twelve trailing months.
Volume
Today’s last reported volume for Regeneron Pharmaceuticals is 68273 which is 84.31% below its average volume of 435354.
